Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US81749D1072
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001J19ZJ7
SERA
Sera Prognostics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Sera Prognostics Inc
ISIN
US81749D1072
TICKER
SERA
MIC
XNAS
REUTERS
SERA.OQ
BLOOMBERG
SERA US
Tue, 23.06.2026       Sera Prognostics
US81749D1072

--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk--SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Dire...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2026....
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, aft...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025....
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.03.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 20...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 17, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 46th Annual Health Care Conference on Monday, Ma...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Sera Prognostics
US81749D1072

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.SALT LAKE CITY, Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Sera Prognostics
US81749D1072

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this yearSALT LAKE CITY, Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended Septe...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 30.10.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report third quarter fiscal year 2025 financial res...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, M...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6,...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences:...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.05.2025       Sera Prognostics
US81749D1072

Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announce...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025....
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 20...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further an...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 19.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024....
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.03.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offerin...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.01.2025       Sera Prognostics
US81749D1072

Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today ann...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Sera Prognostics
US81749D1072

SALT LAKE CITY, Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking plac...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.12.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.12.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on Decemb...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.11.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Healt...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.11.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024....
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.10.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.09.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright Global Investment Conference on Wednesda...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.08.2024       Sera Prognostics
US81749D1072

SALT LAKE CITY, Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: ...
Read more
Sera Prognostics
Technical Analysis Termsheets Terminal
Permalink